Physician profile
Matthew Robert Sullivan
NPI 1538990015
$1,782.09
in general payments reported to CMS, 2019-2025
33 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.14 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $271.62 | 2025 | Enhertu, Lynparza, Calquence |
| Astellas Pharma US INC | $159.94 | 2025 | Vyloy, Padcev, Xospata |
| Janssen Biotech, INC. | $143.72 | 2025 | Erleada, Balversa, Darzalex |
| Novartis Pharmaceuticals Corporation | $131.46 | 2025 | |
| Dendreon Pharmaceuticals LLC | $106.12 | 2025 | Provenge |
| Array Biopharma INC | $64.21 | 2025 | Mektovi, Braftovi, Tukysa |
| Incyte Corporation | $62.72 | 2025 | Monjuvi, Jakafi, Zynyz |
| Genentech USA, INC. | $62.61 | 2025 | Phesgo, Polivy, Venclexta |
| Adc Therapeutics America, INC. | $60.96 | 2025 | |
| Pfizer INC. | $59.61 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $52.75 | 2025 | Opdivo |
| Tersera Therapeutics LLC | $45.93 | 2025 | Zoladex |
| Novocure INC. | $45.38 | 2025 | Optune Gio |
| Merck Sharp & Dohme LLC | $40.63 | 2025 | Keytruda, Welireg |
| Gilead Sciences, INC. | $37.69 | 2025 | Trodelvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.38 | 2025 | |
| Glaxosmithkline, LLC. | $35.96 | 2025 | Ojjaara |
| Lilly USA, LLC | $35.36 | 2025 | Verzenio, Jaypirca |
| Geron Corporation | $33.70 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $30.74 | 2025 | Libtayo |
| Abbvie INC. | $28.06 | 2025 | |
| Emd Serono, INC. | $27.83 | 2025 | |
| Menarini Silicon Biosystems, INC. | $27.16 | 2025 | Cellsearch |
| Immunocore Limited | $25.88 | 2025 | Kimmtrak |
| Takeda Pharmaceuticals U.S.A., INC. | $22.87 | 2025 | Ninlaro |
| Genzyme Corporation | $19.13 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.73 | 2025 | Ultomiris |
| Sobi, INC | $17.44 | 2025 | |
| Sumitomo Pharma America, INC. | $16.73 | 2025 | Orgovyx |
| Daiichi Sankyo INC. | $16.66 | 2025 | Enhertu |
| Agios Pharmaceuticals, INC. | $15.12 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $14.22 | 2025 | |
| Genmab U.S., INC. | $13.77 | 2025 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.